關於虛擬資產現貨ETF上市通知
詳情
關於中達證券上調美股交易徵費率及交收周期變更通知 (更新: 2024年5月17日)
詳情
關於中達證券上調最優惠利率的通知 (更新: 2023年10月31日)
詳情
關於中達證劵修訂投資產品收費表/香港股票交易佣金收費表的通告和最新修訂客戶協議書版本
詳情
有關法拉帝(FERRETTI)-09638.HK,普拉達 (Prada) -01913.HK股份凈買入需繳納意大利金融交易稅
詳情
有關冒充中達證券內部帳戶抽新股的嚴正聲明
詳情
關於不接受第三者存款及現金存款的通知
詳情
有關冒充中達期貨進行詐騙及違法行為的嚴正聲明
詳情
證監會及警務處提醒投資者注意社交媒體上的騙局
詳情 x
Home
Financial
Today IR news
Back
MegaPro’ s MPB-1734 Expected to Seek Prostate Cancer NDA via 505(b)(2) Pathway Supported by Bioequivalence Study
2025-06-30 10:05


EQS Newswire / 30/06/2025 / 10:05 UTC+8

Taipei, June 30, 2025 —MegaPro Biomedical Co., Ltd. (hereafter referred to as “MegaPro”, TPEx: 6827) announced that it has received a written response from the U.S. FDA regarding its novel anti-cancer formulation, MPB-1734, following a Type C meeting. The formulation is based onMegePro’s  proprietary nano-micelle platform and does not contian Tween-80. Based on current nonclinical (animal) and partial human clinical data, FDA considered MPB-1734 for the treatment of prostate cancer may be eligible to use a bioequivalence (BE) study served as a scientific bridge, allowing MPB-1734 to seek regulatory approval through the 505(b)(2) NDA pathway.
Dr. Yuan-Hung Hsu, President of MegaPro, explained that the company’s nano-micelle technology is designed to improve the solubility of poorly water-soluble hydrophobic drugs. Traditionally, these drugs use Tween-80 as a solubilizer. However, scientific studies has indicated that Tween-80 is associated with hypersensitivity reactions. For instance, the label of the marketed drug  Jevtana® includes a black box warning highlighting the risk of severe allergic reactions due to its Tween-80 content,.
MPB-1734, is a Tween-80 free formulation, offering improved drug stability and solubility while reducing excipient-associated risks.
Based on the preclinical and early clinical pharmacokinetic data showing similarity to the reference drug, the US  FDA has indicated that MPB-1734 may be eligible for the 505(b)(2) NDA pathway through a bioequivalence study.
MPB-1734 is a novel formulation taegeting the current market of Jevtana®.  According to Verified Market Reports, the global market size of Jevtana is USD $350 million in 2024 and  projected to reach $750 million by 2033, with a compound annual growth rate (CAGR) of 9.2%,. Key drivers include increasing awareness of prostate cancer, an aging global population, earlier diagnosis, longer survival, and the need for advanced treatment. As a  Tween-80 free formulation, MPB-1734 is well positioned as c competitive alternative in a growing market segment.
Dr. Jassy Wang, CEO of MegaPro, added that recent market cases—such as Cinvanti (a Tween-80 free antiemetic) and BEIZRAY (Tween-80 free paclitaxel) demonstrated that new formulation without Tween-80 not only obtained  regulatory approvals via bioequivalence studies but also rapidly gained market share or achieved successful  out-licensing after launch.
This validates MegaPro's commercial potential of its nano-micelle platform. The company aims to apply this technology to re-formulate hydrophobic drugs, thus to accelerate regulatory  timeline and reach new milestone in business growth.

30/06/2025 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com